Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance

NARecruitingINTERVENTIONAL
Enrollment

2,298

Participants

Timeline

Start Date

October 3, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Barrett EsophagusBarretts Esophagus With DysplasiaEsophageal Adenocarcinoma
Interventions
DIAGNOSTIC_TEST

Seattle protocol

Participants undergo 4-quadrant biopsies with standard biopsy forceps taken at 2 cm intervals. For participants undergoing a confirmatory endoscopy for cases in which discordant results are noted (WATS3D positive for dysplasia/cancer and Seattle biopsy negative for dysplasia/cancer), repeat biopsies will be taken at 1 cm intervals along with target biopsies from any visible lesions.

DIAGNOSTIC_TEST

WATS3D brushings

Participants undergo 2 WATS3D biopsies of every 5 cm segment of Barrett's esophagus, starting from the gastroesophageal junction and moving proximally through the entire segment of Barrett's.

Trial Locations (14)

10065

RECRUITING

Weill Cornell Medicine, New York

11040

RECRUITING

Long Island Jewish Medical Center, New Hyde Park

14642

RECRUITING

University of Rochester, Rochester

17822

RECRUITING

Geisinger Medical Center, Danville

27599

RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

34239

RECRUITING

Suncoast Endoscopy of Sarasota, Sarasota

37909

RECRUITING

Gastrointestinal Associates, PC, Knoxville

55905

RECRUITING

Mayo Clinic, Rochester

60611

RECRUITING

Northwestern University, Chicago

80045

RECRUITING

University of Colorado Anschutz Medical Campus, Aurora

85295

RECRUITING

Arizona Centers of Digestive Health, Gilbert

90024

RECRUITING

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

94611

RECRUITING

Kaiser Permanente, Oakland

06010

RECRUITING

Connecticut Clinical Research Institute, Bristol

All Listed Sponsors
lead

University of Colorado, Denver

OTHER